( PHILADELPHIA--(BUSINESS WIRE)--Apr 16 ...)AVAX Technologies Presents Results of Phase I-II M-Vax Trial at,Annual Meeting of American Association for Cancer Research,Health

PHILADELPHIA--(BUSINESS WIRE)--Apr 16, 2007 - AVAX Technologies, Inc. (OTCMarket:AVXT.OB) today announces that it is presenting the initial results of its Phase I-II trial of M-Vax(TM) for patients with metastatic melanoma at a Clinical Research session of the meeting of the American Association for Cancer Research. M-Vax(TM) is composed of autologous melanoma cells that have been irradiated and then modified with the hapten, dinitrophenyl (DNP).

"AVAX is pleased with the results of this trial," commented Dr. David Berd, Chief Medical Officer and presenter of the paper. "This is a bridging study to verify that the immunological responses induced by M-Vax(TM) are similar to those observed with an earlier version of the vaccine developed and tested by my laboratory at Thomas Jefferson University. We now have identified at least one dose of M-Vax(TM) that induces DTH to DNP-modified and unmodified autologous melanoma cells at a rate similar to what we observed previously. So far, the safety profile looks excellent, as we expected."

The study included patients with stage III and IV melanoma whose tumor tissue could be obtained for vaccine production. They were assigned in a double blind fashion to one of four dosage arms of M-Vax(TM), including a placebo arm that contained no vaccine cells. The results of the first 54 evaluable patients are being presented, and the blinding of the dosage arm assignments has been preserved. As determined by the two-step design of the trial, one dosage arm was declared "positive" with 17/22 patients exhibiting a positive DTH response to autologous, DNP-modified melanoma cells post-M-Vax(TM) and 7/18 exhibiting a positive response to autologous unmodified cells. A second dosage arm was declared "negative" with only 2/8 responders. The efficacy of the other two dosage arms cannot yet be categorized. No patients exhibited DTH to the negative control material.

Richard Raine
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
4. Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction
5. Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at 20th International Conference on Antiviral Research Meeting
6. Micell Technologies Presents Data on Novel Drug-Eluting Stents
7. OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting
8. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
9. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
10. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
11. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop